AU2012240077C1 - Hsp90 inhibitors - Google Patents

Hsp90 inhibitors Download PDF

Info

Publication number
AU2012240077C1
AU2012240077C1 AU2012240077A AU2012240077A AU2012240077C1 AU 2012240077 C1 AU2012240077 C1 AU 2012240077C1 AU 2012240077 A AU2012240077 A AU 2012240077A AU 2012240077 A AU2012240077 A AU 2012240077A AU 2012240077 C1 AU2012240077 C1 AU 2012240077C1
Authority
AU
Australia
Prior art keywords
substituted
alkynyl
unsubstituted
straight
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012240077A
Other languages
English (en)
Other versions
AU2012240077A1 (en
AU2012240077B2 (en
Inventor
Gabriela Chiosis
Pallav Patel
Weilin Sun
Tony Taldone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2012240077A1 publication Critical patent/AU2012240077A1/en
Application granted granted Critical
Publication of AU2012240077B2 publication Critical patent/AU2012240077B2/en
Publication of AU2012240077C1 publication Critical patent/AU2012240077C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012240077A 2011-04-05 2012-04-05 Hsp90 inhibitors Ceased AU2012240077C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472061P 2011-04-05 2011-04-05
US61/472,061 2011-04-05
PCT/US2012/032371 WO2012138894A1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Publications (3)

Publication Number Publication Date
AU2012240077A1 AU2012240077A1 (en) 2013-10-31
AU2012240077B2 AU2012240077B2 (en) 2017-04-20
AU2012240077C1 true AU2012240077C1 (en) 2017-08-10

Family

ID=48166734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012240077A Ceased AU2012240077C1 (en) 2011-04-05 2012-04-05 Hsp90 inhibitors

Country Status (11)

Country Link
US (2) US9346808B2 (OSRAM)
EP (1) EP2694505B1 (OSRAM)
JP (1) JP6266506B2 (OSRAM)
KR (1) KR102010222B1 (OSRAM)
CN (1) CN103582642B (OSRAM)
AU (1) AU2012240077C1 (OSRAM)
BR (1) BR112013025634A2 (OSRAM)
CA (1) CA2832530C (OSRAM)
EA (1) EA201391334A1 (OSRAM)
MX (1) MX360390B (OSRAM)
WO (1) WO2012138894A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
CN104081203B (zh) 2011-07-08 2018-07-31 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3033338A4 (en) 2013-08-16 2017-06-14 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof
RU2016128528A (ru) * 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
AU2015317632B2 (en) * 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EA201890623A1 (ru) 2015-10-05 2018-09-28 Мемориал Слоун Кеттеринг Кэнсер Сентр Рациональная комбинированная терапия для лечения рака
KR20200019220A (ko) * 2017-06-23 2020-02-21 사무스 테라퓨틱스, 인코포레이티드 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
WO2009065035A1 (en) * 2007-11-14 2009-05-22 Myriad Genetics, Inc. Therapeutic compounds and their use in treating diseases and disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
EP1335920B1 (en) 2000-11-02 2013-04-03 Sloan-Kettering Institute For Cancer Research Compositions containing purine derivatives for binding to hsp90
JP2005505506A (ja) 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
JP2005524661A (ja) 2002-02-28 2005-08-18 アストラゼネカ アクチボラグ ３−シクリル−５−（窒素含有５員環）メチル−オキサゾリジノン誘導体と抗菌剤としてのその使用
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007075572A2 (en) 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
FR2906824B1 (fr) 2006-10-09 2008-12-26 Roger Mondelin Sas Soc Par Act Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US20080234297A1 (en) * 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
WO2009007399A1 (en) 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2786715C (en) 2009-01-16 2019-05-21 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
WO2011006206A1 (en) * 2009-07-17 2011-01-20 Paftec Holdings Pty Ltd Respirator
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
NZ599138A (en) 2009-10-07 2014-06-27 Sloan Kettering Inst Cancer Purine derivatives useful as hsp90 inhibitors
CA2832530C (en) 2011-04-05 2021-02-16 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
EP3033338A4 (en) 2013-08-16 2017-06-14 Memorial Sloan-Kettering Cancer Center Selective grp94 inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
WO2009065035A1 (en) * 2007-11-14 2009-05-22 Myriad Genetics, Inc. Therapeutic compounds and their use in treating diseases and disorders

Also Published As

Publication number Publication date
WO2012138894A4 (en) 2012-12-06
US9346808B2 (en) 2016-05-24
EA201391334A1 (ru) 2014-06-30
EP2694505A1 (en) 2014-02-12
KR102010222B1 (ko) 2019-08-13
JP6266506B2 (ja) 2018-01-24
AU2012240077A1 (en) 2013-10-31
CN103582642A (zh) 2014-02-12
MX360390B (es) 2018-10-31
NZ616758A (en) 2016-01-29
KR20140062429A (ko) 2014-05-23
BR112013025634A2 (pt) 2016-07-19
US9926321B2 (en) 2018-03-27
US20160264577A1 (en) 2016-09-15
WO2012138894A1 (en) 2012-10-11
EP2694505B1 (en) 2022-04-27
CA2832530C (en) 2021-02-16
CA2832530A1 (en) 2012-10-11
AU2012240077B2 (en) 2017-04-20
JP2014510148A (ja) 2014-04-24
MX2013011532A (es) 2014-08-22
US20140088121A1 (en) 2014-03-27
CN103582642B (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
AU2012240077C1 (en) Hsp90 inhibitors
AU2012240079B2 (en) Hsp90 inhibitors
EP4592296A1 (en) Novel tetraheterocycle compound
CA2730271A1 (en) Pi3k isoform selective inhibitors
CA2705579A1 (en) Therapeutic compounds and their use in treating diseases and disorders
CA3077267A1 (en) Fused heteroaryl ring derivatives useful as a2a receptor inhibitor
WO2020103939A1 (zh) 三唑并环类化合物、其制备方法、中间体和应用
HK1194376A (en) Hsp90 inhibitors
HK1194376B (en) Hsp90 inhibitors
HK1194375B (en) Hsp90 inhibitors
HK1194375A (en) Hsp90 inhibitors
NZ616758B2 (en) Hsp90 inhibitors
JP2017061540A (ja) Ｈｓｐ９０阻害物質
NZ616890B2 (en) Hsp90 inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 APR 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 APR 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired